Last reviewed · How we verify
Hib-MenCY-TT vaccine
This vaccine stimulates the immune system to produce antibodies against Haemophilus influenzae type b, Neisseria meningitidis serogroups C and Y, and tetanus toxin.
This vaccine stimulates the immune system to produce antibodies against Haemophilus influenzae type b, Neisseria meningitidis serogroups C and Y, and tetanus toxin. Used for Prevention of invasive disease caused by Haemophilus influenzae type b, Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups C and Y, Prevention of tetanus.
At a glance
| Generic name | Hib-MenCY-TT vaccine |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Conjugate vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
Hib-MenCY-TT is a conjugate vaccine that combines polysaccharide antigens from three bacterial pathogens linked to tetanus toxoid as a carrier protein. This conjugation enhances immunogenicity by promoting T-cell dependent B-cell responses, resulting in robust antibody production and immunological memory against invasive bacterial infections caused by Hib, meningococcal serogroups C and Y, and tetanus.
Approved indications
- Prevention of invasive disease caused by Haemophilus influenzae type b
- Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups C and Y
- Prevention of tetanus
Common side effects
- Injection site erythema
- Injection site swelling
- Fever
- Irritability
Key clinical trials
- Immuno,Safety of GSK Vaccine 134612 Given at Age of 12-15 Months 15-18 Months Post-priming With GSK Vaccine 792014 (PHASE3)
- Immunogenicity, Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Hib-MenCY-TT (MenHibrix®) Vaccine Compared to Merck & Co, Inc. PedvaxHIB Vaccine in Healthy Infants and Toddlers 12 to 15 Months of Age (PHASE3)
- Dose Ranging Study of Combined Haemophilus Influenzae Type B-Meningococcal Serogroups CY (Hib-MenCY-TT) Vaccine (PHASE2)
- 3 Formulations of Hib-MenCY-TT Vaccine & 1 Formulation of Hib-MenC-TT Vaccine Compared to Licensed Meningococcal Serogroup C Conjugate Vaccine, Each Administered at 2,3,4 Mths of Age (PHASE2)
- Comparison of GSKBiologicals' Hib-MenCY-TT Vaccine vs Licensed Hib Conjugate or Meningococcal Vaccine (PHASE2)
- Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine (PHASE3)
- Hib-MenCY-TT Vaccine Study Compared to Licensed Hib and Meningococcal Serogroup C Conjugate Vaccines (PHASE2)
- Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 2, 4, 6 and 12 to 15 Months of Age (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hib-MenCY-TT vaccine CI brief — competitive landscape report
- Hib-MenCY-TT vaccine updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI